Lataa...
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Common end points for phase II trials in patients with glioblastoma multiforme (GBM) are six-month progression-free survival (PFS6) and 12-month overall survival (OS12). OS12 can be accurately measured but may be confounded with subsequent therapies upon progression, whereas the converse is true for...
Tallennettuna:
| Päätekijät: | , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Duke University Press
2007
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1828103/ https://ncbi.nlm.nih.gov/pubmed/17108063 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2006-025 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|